



COMMUNICATION OF OTHER RELEVANT INFORMATION

7 May 2024

In accordance with the provisions of article 227 of Law 6/2023 of 17 March on Securities Markets and Investment Services and other related provisions, the following information relating to ATRYS HEALTH, S.A. ("**ATRY**S") is made available to the market:

The Board of Directors of ATRYS has resolved, on 7 May 2024, pursuant to the delegation of the Extraordinary General Meeting of Shareholders of 21 December 2023, to carry out an issue of contingent convertible bonds into shares (the "**Bonds**") with the same terms and conditions as the Bonds issued on 28 December 2023:

- Effective amount: €11,700,000 (the "**Issue Amount**" or the "**Issue Price**").

The Bonds shall be represented by registered securities, each with a nominal value of ONE HUNDRED THOUSAND EUROS (€100,000).

- Interest rate: The Bonds will accrue from the subscription date an interest rate of 9.50% per annum. To the Issue Amount will be added accrued interest which will be capitalized at the PIK Interest Rate (the "**Conversion Amount**").
- Conversion of the Bonds: Each Bond will entitle its holder to convert such Bond into new ordinary shares of the Company. The number of ordinary shares to be issued or delivered to each Bondholder:

(a) in the event of exercise of the conversion right, shall be determined by dividing the Conversion Amount by seven euros; and

(b) in the event of a mandatory conversion, shall be determined by dividing the Conversion Amount by the lesser of: (i) the weighted average price per ordinary share over one hundred (100) consecutive trading days, and (ii) the weighted average price per ordinary share over thirty (30) consecutive trading days, applying in both (i) and (ii) above a discount of ten per cent (10%) or such percentage discount in excess of ten per cent (10%) and not exceeding twenty per cent (20%) as may be justified by the management body.

Each Bondholder shall, by individual decision, have the right to request conversion, inter alia, at any time from the date of the expiry of 6 months from the subscription date until the date of the expiry of 72 months from the subscription date.

- Maturity: The Bonds will mature on the date seventy-eight (78) months after the subscription date if the conversion option is not exercised or a mandatory conversion event does not occur.



- Fungibility of the Bonds: The Bonds are fungible with the contingent convertible bonds that the Issuer issued on 28 December 2023 for a nominal amount of 13,300,000 euros under the authorization approved by the Ordinary General Meeting of the Company dated December 21, 2023.

In addition, today the disbursement of the Bonds amounting to 11.7 million euros was executed, so ATRYS has successfully completed the issuance of Contingent Convertible Bonds.

Madrid, 7 May 2024

ATRYS HEALTH, S.A.

Ms. Isabel Lozano Fernández
Chief Executive Officer (CEO)